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EDITORIAL
Risk factors for renal cell carcinoma: Hypertension or diuretics?
Hypertension has been documented to be a general risk
factor for cancer [1–3]. This is perhaps not surprising be-
cause both hypertension and cancer share some common
risk factors, such as smoking, diabetes, obesity, alcohol
consumption, etc. One, therefore, expects a hypertensive
population to be at a higher risk of any cancer than a com-
parative normotensive population, and a recent meta-
analysis showed the excess cancer risk to be around 20%
to 30% [3]. A closer scrutiny of the cancer type revealed
that the renal cell carcinoma seemed to be particularly
closely associated with hypertension [4]. This begs the
question whether renal cell carcinoma is linked to hyper-
tension, per se, or to its sequela (i.e., antihypertensive
therapy). Among the potential suspects, diuretics, pre-
dominantly of the thiazide type, have been identified as
the most likely perpetrators.
In the present issue of Kidney International, Choi et al
[5] examined a cohort of more than 500,000 Korean men,
60% of whom were smokers, over a period of up to 8 years.
Hypertension proved to be a strong and independent risk
factor for kidney cancer mortality. Smokers with systolic
blood pressure above 160 mm Hg had a risk of renal cell
carcinoma that was 8 times higher than for those with a
blood pressure of less than 120 mm Hg. However, the as-
sociation between hypertension and renal cell carcinoma
was independent of smoking and other covariants. Hy-
pertensive patients had a 2.43 greater risk of dying from
renal cell carcinoma than normotensive subjects, and pa-
tients with stage 3 hypertension had an almost 4-fold risk.
This, and many other studies, does not allow us to discern
whether hypertension, per se, is a carcinogenic disease
state, or whether the renal cell carcinoma risk is asso-
ciated with long-term exposure to diuretic therapy [6].
Arguments for both pathogenetic links can easily be put
forward (Table 1).
An attempt to dissociate the risk of hypertension on
renal cell carcinoma from the risk of long-term diuretic
therapy has been increasingly futile. In most studies doc-
umenting an increased risk of renal cell carcinoma with
thiazide diuretics, the significance of this association be-
came less pronounced when adjusted for the presence
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of hypertension, although in 5 out of 10 case control
studies, diuretic therapy remained a significant risk factor
even after adjustment. There is no question that, statis-
tically and epidemiologically, the effect of diuretics can
elegantly be separated from the effects of hypertension.
However, as clinicians, we should perhaps remember that
any patient who has been hypertensive for more than 2
to 3 decades was treated at one time or the other with a
thiazide diuretic, even if he or she does no longer recall
ever having taken a fluid pill. A myriad of fixed combi-
nations containing thiazide diuretics have been, and still
are, extensively used in antihypertensive therapy. Thus,
diuretic therapy is intrinsically linked to hypertension. It
seems therefore most likely that the common denomi-
nator between hypertension and renal cell carcinoma is
actually diuretic therapy, just as the common denomina-
tor between chronic obstructive pulmonary disease and
lung cancer is cigarette smoking. The chronic chemical
bombardment of the tubular cells over years and decades
seems to have a low-grade carcinogenic effect.
Reassuringly, the risk of renal cell carcinoma associ-
ated with diuretics is relatively low. Based on an 8-year
incidence of new cases of renal cell carcinoma in 35,192
women, the absolute risk amounted to 16 cases of renal
cell carcinoma per 100,000 patient years [15]. The MRC
study [16] and SHEP [17] allow us to calculate that for
one patient with renal cell carcinoma, between 20 and 40
strokes, between 3 and 30 coronary events, and between
4 and 18 deaths could be avoided with diuretic therapy.
The risk of renal cell carcinoma may be somewhat higher
in younger to middle-aged women because they are less
protected than men against heart attack or stroke by the
same diuretic therapy, they use more diuretics than men
do, and, in contrast to natural history where there is a dis-
tinct male predominance, diuretic-associated renal cell
carcinoma is twice as common in women as it is in men.
Premenopausal women may be more susceptible to the
risk of renal cell carcinoma because estrogens have been
shown to enhance the density of the thiazide sensitive
NaC1 transporter in the distal tubule [11]. Interestingly
enough, the study of Choi et al [5] is the first one that
shows a several-fold increased risk of kidney cancer in
Korean men, most of who were smokers.
In conclusion, the study of Choi et al is yet another
tessera in the mosaic that hypertension, or its therapy,
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Table 1. Evidence possibly linking diuretic therapy and hypertension to renal cell carcinoma
Evidence possibly linking diuretic therapy and hypertension to renal cell carcinoma
Hydrochlorothiazide is a cyclic imide that can be converted to a mutagenic nitroso derivative in the stomach [7, 8].
Rats and mice treated with diuretics develop nephropathy and renal adenomas [9, 10].
Case control and cohort studies indicate a relative risk of renal cell carcinoma with diuretics between 1.2 and 4.5 [6].
The risk of renal cell carcinoma was related to duration of diuretic therapy in some studies.
Diuretic-associated renal cell carcinoma has an inverse gender predominance (more common in women than in men), and estrogens enhance
thiazide effects on tubular cells [11].
After thiazide treatment the distal tubular cells in rats look like tumor cells and exhibit markers for tumor cells [12].
The renal tubular cell (i. e., the cell that becomes neoplastic) is the target site of the diuretic’s main pharmacologic effect.
Evidence possibly linking hypertension to renal cell carcinoma
Accelerated cell proliferation may be a common pathophysiologic feature of hypertension and cancer.
Free insulin-like growth factor that is elevated in hypertension, particularly in the obese, is an important mitogen that has been linked to an
increased risk of several cancers [13, 14].
Subtle changed in renal function preceding the development of either overt hypertension may render the kidney susceptible to carcinogens and
tumor growth.
The pathogenesis of both hypertension and cancer in general has been associated with chronic low-grade inflammation.
Hypertensive patients are more frequently examined than normotensive subjects and the odds of finding any cancer increases with more
physician visits.
increases the risk of renal cell carcinoma. The common
denominator between the hemodynamic and neoplastic
disorders may well be diuretic therapy. Accordingly, di-
uretics should be used thoughtfully in low doses only,
and preferentially in combination with other antihyper-
tensive drugs. We need to address the question whether
patients with longstanding hypertension who have been
exposed to diuretic therapy for decades require to be
screened periodically for occult renal cell carcinoma.
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